CLAIMS

1. A recombinant oncolytic Herpes Simplex virus (HSV) comprising an expression cassette encoding a C-terminal fragment of PTEN-Long, wherein the C-terminal fragment is at least 90% identical to the amino acid sequence encoded by SEQ ID NO:1.

2. The recombinant oncolytic HSV of claim 1, wherein the C-terminal fragment is at least 99% identical to the amino acid sequence encoded by SEQ ID NO:1.

3. The recombinant oncolytic HSV of claim 1, wherein the amino acid sequence of the C-terminal fragment comprises 173 fewer amino acids at the N-terminus relative to the amino acid sequence encoded by SEQ ID NO:1.

4. The recombinant oncolytic HSV of any one of claims 1 to 3, wherein the expression cassette comprises a tumor-specific promoter.

5. The recombinant oncolytic HSV of any one of claims 1 to 4, wherein the recombinant virus comprises a HSV-1 backbone.

6. The recombinant oncolytic HSV of any one claims 1 to 5, wherein the expression cassette comprises a tissue specific promoter.

7. The recombinant oncolytic HSV of any one of claims 1 to 5, wherein the expression cassette comprises an inducible promoter.

8. The recombinant oncolytic HSV of any one of claims 1 to 5, wherein the expression cassette comprises a constitutive promoter.

9. Use of the recombinant oncolytic HSV of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of a cancer in a subject.

10. Use of the recombinant oncolytic HSV of any one of claims 1 to 8 in the manufacture of a medicament for inhibiting PD-L1 in a cancer cell in a subject.

11. Use of the recombinant oncolytic HSV of any one of claims 1 to 8 in the manufacture of a medicament for increasing the number of infiltrating CD8 T cells or Natural Killer cells at the site of a cancer in a subject.

12. Use of the recombinant HSV of any one of claims 1 to 8 in the manufacture of a medicament for inhibiting the metastasis of a cancer in a subject.